Daveen Chopra - 11 May 2026 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Reporting relationship: CVP, TMTT & Surgical
Issuer ticker: EW
Reported as of: 11 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 May 2026, 16:50:35 UTC
Prior SEC filing: 08 May 2026
Next SEC filing: 22 May 2026
Source filing: View source filing
Reporting owner signature: Linda J. Park, Attorney-in-Fact

Key filing fact

Daveen Chopra filed Form 4 for Edwards Lifesciences Corp (EW) on 12 May 2026.

Key facts

This page summarizes Daveen Chopra's Form 4 filing for Edwards Lifesciences Corp (EW).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 May 2026, 16:50.

Change

Previous filing in this sequence was filed on 08 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001740963 Primary reporting owner

Chopra Daveen

Relationship: CVP, TMTT & Surgical
Address: ONE EDWARDS WAY, IRVINE
Signature: Linda J. Park, Attorney-in-Fact
Signature date: 11 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EW transaction

Common Stock

Options Exercise

Transaction value
Shares: +13,583
Change %: +34%
Price: $0.000000^*
Shares after: 53,362
Date: 11 May 2026
Ownership: Direct
Footnotes: F1

EW transaction

Common Stock

Tax liability

Transaction value
Shares: -7,538
Change %: -14%
Price: $79.96^*
Shares after: 45,824
Date: 11 May 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EW transaction Derivative

Performance Rights

Options Exercise

Transaction value
Shares: -13,583
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 11 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,583
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4.

Footnote F2

These Performance Rights expire on May 10, 2030.

SEC remarks

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.